Market
Will Absci report an AI-driven drug discovery breakthrough by mid-2026?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Scientific publications or Absci's official announcements
Story
AMD Invests $20M in AI-Driven Absci Structured as PIPE to Boost Drug Discovery Efforts
Jan 8, 2025, 11:50 AM
Advanced Micro Devices (AMD) has made a $20 million investment in Absci Corporation (ABSI), a company focused on AI-driven drug discovery. This strategic investment, reported by the Wall Street Journal, is part of AMD's initiative to market its AI semiconductors to the healthcare sector. The investment is structured as a private investment in public equity (PIPE) and aims to assist Absci in reducing its hardware costs by migrating some of its workloads to AMD's technology. This move underscores AMD's commitment to expanding its presence in the healthcare industry through innovative AI applications.
View original story
Similar markets
Cancer treatment • 25%
Bacterial infections • 25%
Autoimmune diseases • 25%
Viral infections • 25%
Yes • 50%
No • 50%
No further development • 25%
Phase 1 Clinical Trials • 25%
Licensing Agreement • 25%
Partnership with NGO • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
Pfizer • 25%
Performance is similar • 25%
Nvidia GPUs outperform AMD GPUs • 25%
No clear comparison available • 25%
AMD GPUs outperform Nvidia GPUs • 25%
Lasker Award • 25%
No major award • 25%
Breakthrough Prize • 25%
Nobel Prize • 25%
3-5 discoveries • 25%
6-8 discoveries • 25%
More than 8 discoveries • 25%
0-2 discoveries • 25%